Inmunotek, a Spanish biotechnology company, has built its research platform around a deceptively simple idea: chemically modifying allergens so they train the immune system without triggering dangerous allergic reactions. The company’s work spans classical allergy vaccines, sublingual delivery systems, and a newer line of mucosal bacterial preparations that tap into a phenomenon called trained immunity. Together, these products represent a broadening vision for what immunotherapy can do, moving beyond seasonal sneezing into territory like recurrent infections and asthma prevention.
How Allergen Immunotherapy Retrains the Immune System
Allergy immunotherapy works by gradually exposing a person to increasing amounts of the substance they’re allergic to, whether that’s pollen, dust mites, or mold. Over months and years, this exposure shifts the immune system’s response. The body generates regulatory T cells that dampen the overreaction driving allergy symptoms. These regulatory cells release a signaling molecule called IL-10, which encourages B cells to produce a different class of antibody, IgG4, instead of the IgE antibodies responsible for allergic reactions.1PubMed Central. Update in the mechanisms of allergen-specific immunotheraphy At the same time, the cells that cause acute allergic symptoms, including mast cells, eosinophils, and basophils, become less active.2PubMed. Immunological mechanisms of allergen-specific immunotherapy
This is a genuine immune recalibration, not just symptom suppression. Antihistamines and nasal steroids manage symptoms while you take them. Immunotherapy aims to change the underlying immune response so that symptoms stay reduced or gone even after treatment ends. That distinction matters because it opens the door to disease modification, a concept that becomes especially important when we get to asthma prevention.
Allergoids and the Problem They Solve
Traditional immunotherapy uses native allergen extracts, which means the same proteins that make you sneeze and wheeze are the ones being injected or placed under your tongue. The challenge is obvious: giving an allergic person their allergen risks provoking the very reaction you’re trying to treat. Dose escalation has to be cautious and slow, which stretches treatment timelines.
Allergoids are allergen extracts that have been chemically modified, typically with glutaraldehyde or formaldehyde, to reduce their ability to bind IgE antibodies while preserving the structural features the immune system needs to build a tolerant response. Inmunotek’s approach uses glutaraldehyde treatment combined with depigmentation, a process that strips out low-molecular-weight irritants. The result is a larger, aggregated molecule that the immune system can still recognize and learn from, but that is far less likely to cross-link the IgE antibodies sitting on mast cells and trigger an allergic flare.
Laboratory work has shown that glutaraldehyde-treated allergoids produce significantly less leukotriene release from mast cells compared with unmodified extracts at lower concentrations, while also reducing T-cell activation when processed through dendritic cells.3PubMed Central. Reduced in vitro T-cell responses induced by glutaraldehyde-modified allergen extracts are caused mainly by retarded internalization of dendritic cells In practical terms, this means the modified vaccine can deliver a stronger immune-training dose with a lower risk of triggering a reaction.
The Safety Record of Modified Allergen Vaccines
Safety data from clinical use bears out the laboratory findings. A study tracking patients receiving depigmented, polymerized allergen vaccines found that systemic reactions of moderate or higher severity occurred in just 0.12% of injections. All systemic reactions were mild and resolved on their own without medication.4PubMed. Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts A separate study evaluating the same type of vaccine reported local reaction rates of about 2.4 per thousand injections and systemic reaction rates of about 4.6 per thousand, with the best safety profile seen in patients treated for house-dust mite allergy.5PubMed. Safety of a depigmented, polymerized vaccine for the treatment of allergic rhinoconjunctivitis and allergic asthma
These rates are lower than what is typically reported for unmodified allergen extracts. The clinical significance is that fewer adverse reactions mean faster dose escalation, fewer clinic visits, and a more tolerable experience for the patient, all of which improve the odds that someone will actually finish their treatment course.
Sublingual Delivery and Carbamylated Monomeric Allergoids
Immunotherapy has historically meant repeated injections at a doctor’s office. Sublingual immunotherapy, where a tablet or drops are placed under the tongue daily at home, removes that barrier. The oral mucosa is rich in dendritic cells that have a natural tendency toward tolerance rather than inflammation, making it an efficient site for immune education.6PubMed. Dendritic cells as potential targets for mucosal immunotherapy Research mapping the immune architecture under the tongue has confirmed clusters of immune cells and dendritic cell networks that could be leveraged for both vaccination and tolerance induction.7The Journal of Clinical Investigation. Sublingual immune cell clusters and dendritic cell distribution in the oral cavity
Inmunotek has developed carbamylated monomeric allergoids (CMAs) specifically for sublingual use. The carbamylation process chemically modifies the allergen to reduce IgE binding, similar in goal to glutaraldehyde polymerization, but it produces a smaller molecule rather than a larger aggregate. That smaller size is better suited for absorption through the thin mucosal lining under the tongue.8PubMed Central. Carbamylated monomeric allergoids for sublingual immunotherapy in pediatric respiratory allergies
Pharmacovigilance data on CMA tablets is striking. Across more than 15 million administered doses, only 25 spontaneous reports of adverse drug reactions were filed, and just two were classified as serious. That works out to a reaction rate of roughly 0.0004% of all doses, far below the rates commonly reported for other sublingual allergen products.9PubMed. The safety of carbamylated monomeric allergoids for sublingual immunotherapy. Data from a pharmacovigilance study Clinical evaluation of shortened up-dosing schedules for sublingual allergoids also found very few adverse reactions, suggesting that patients can reach effective doses quickly.10PubMed Central. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with three different shortened up-dosing administration schedules
The Adherence Problem
Even the safest therapy doesn’t help if patients stop taking it. Immunotherapy requires at least three years for full disease-modifying benefits, and dropout is a pervasive problem across both delivery routes. A nationwide compliance study found that by year three, only about 57% of subcutaneous patients and 53% of sublingual patients were still on treatment.11PubMed. Compliance in subcutaneous and sublingual allergen immunotherapy: A nationwide study Another study from a large allergy center reported dropout rates of about 39% for sublingual and 32% for subcutaneous patients, a gap that was not statistically significant.12PubMed Central. Sublingual versus subcutaneous immunotherapy: patient adherence at a large German allergy center
When researchers have compared “excellent” compliance specifically, subcutaneous patients tend to score higher at every stage of treatment.13PubMed. Immunotherapy compliance: comparison of subcutaneous versus sublingual immunotherapy The intuitive explanation is that office visits create accountability. You have an appointment; you show up. Home-based sublingual therapy relies entirely on self-motivation, and it’s easy to skip a daily dose you don’t feel is doing anything in the short term. This is one reason why innovations that shorten treatment protocols or reduce dosing complexity matter as much as breakthroughs in immunology.
MV130 and Trained Immunity Against Respiratory Infections
Inmunotek’s research extends well beyond classical allergy treatment. MV130 is a sublingual preparation of heat-inactivated bacteria, not an allergen vaccine, designed to prevent recurrent respiratory infections. Its mechanism is fundamentally different from traditional vaccines: rather than teaching the immune system to recognize a specific pathogen, MV130 reprograms innate immune cells to respond more aggressively to a broad range of threats, a phenomenon known as trained immunity.
Animal studies demonstrated that intranasal MV130 protected mice against two unrelated respiratory viruses, reducing both sickness and death. Critically, this protection also held in mice lacking mature B and T cells, confirming that the benefit came from innate immunity rather than the adaptive immune memory used by conventional vaccines.14Cell Reports. Mucosal administration of a fully inactivated bacterial vaccine induces trained immunity and confers protection against viral infections The same preparation protected mice against systemic Candida infection in a standard trained-immunity model, demonstrating that mucosal administration could produce body-wide effects.15PubMed Central. Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections
In real-world human use, MV130’s clinical impact has been substantial. A retrospective study in both children and adults found that the median number of infection episodes dropped by more than 70% in children and more than 80% in adults after MV130 immunization. Antibiotic courses also fell by over 80% in both groups.16PubMed Central. MV130 in the Prevention of Recurrent Respiratory Tract Infections: A Retrospective Real-World Study in Children and Adults These numbers are impressive, though they come from a retrospective design rather than a randomized controlled trial, so some caution is warranted.
The broader implication is that trained-immunity-based mucosal vaccines could offer broad-spectrum protection against respiratory infections, potentially complementing the pathogen-specific protection of conventional vaccines.17Trends in Immunology. Inmunotek: Pioneering Next-Level Allergy Immunotherapy For anyone who catches colds and bronchitis repeatedly each winter, this line of research is worth watching.
MV140 and Recurrent Urinary Tract Infections
The same trained-immunity logic has been applied to a completely different clinical problem. MV140 is a sublingual vaccine containing inactivated bacteria commonly responsible for urinary tract infections. For women who suffer from recurrent UTIs, the current standard is repeated antibiotic courses, which drive resistance and don’t prevent the next episode.
A randomized, placebo-controlled trial published in NEJM Evidence found that women receiving MV140 had a median of zero UTI episodes over the study period, compared with three episodes in the placebo group. More than half of women in both MV140 arms remained completely UTI-free, compared with just a quarter of those on placebo.18PubMed. Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections A longer observational study reported that the UTI-free rate was about 74% at three months post-vaccination, gradually declining to about 45% at two years, with an overall reduction in UTI episodes exceeding 50%.19PubMed. Analysis of the Efficacy of a Sublingual Bacterial Vaccine in the Prophylaxis of Recurrent Urinary Tract Infection
The first North American study of MV140 found a 75% reduction in UTI rates during the nine-month period following vaccination, with about 41% of participants remaining completely infection-free.20PubMed Central. MV140 sublingual vaccine reduces recurrent urinary tract infection in women: Results from the first North American clinical experience study These results suggest that MV140 could eventually reshape how recurrent UTIs are managed, moving from reactive antibiotics toward preventive immunization.
Can Immunotherapy Prevent Asthma?
One of the most consequential questions in allergy research is whether treating allergic rhinitis with immunotherapy can prevent patients from developing asthma down the road. Allergic rhinitis and asthma share immune pathways, and a substantial fraction of people with untreated nasal allergies eventually develop lower-airway disease. If immunotherapy can interrupt that progression, the public health impact would be enormous.
A systematic review and meta-analysis of both randomized and non-randomized studies found that allergen immunotherapy reduced the risk of developing asthma by about 25% overall. In children specifically, the risk dropped by roughly 29%, and in patients sensitized to a single allergen who completed at least three years of therapy, the reduction reached about 50%.21PubMed. Allergen immunotherapy for asthma prevention: A systematic review and meta-analysis of randomized and non-randomized controlled studies A large population-based study using French national health data reported that patients with allergic rhinitis who received sublingual liquid immunotherapy had a 36% lower rate of new asthma events compared with matched controls who did not receive immunotherapy.22The Lancet Regional Health – Europe. Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study)
For children, this is where immunotherapy has its most compelling case. Reviews of pediatric evidence confirm that allergen immunotherapy is safe and effective in children, with demonstrated ability to reduce medication use, prevent new allergen sensitizations, and slow the march from rhinitis to asthma.23PubMed Central. Recent Updates of Immunotherapy for Allergic Rhinitis in Children One head-to-head comparison of subcutaneous and sublingual immunotherapy in children found that both routes improved symptom scores, though subcutaneous treatment showed somewhat greater symptom reduction and higher compliance, while sublingual treatment had fewer adverse events.24PubMed. Compliance, efficacy, and safety of subcutaneous and sublingual immunotherapy in children with allergic rhinitis
Mannan-Conjugated Allergoids and Dendritic Cell Targeting
A more experimental branch of Inmunotek’s pipeline involves conjugating allergoids to mannan, a sugar polymer derived from yeast cell walls. Dendritic cells, the immune system’s sentinels, have surface receptors that avidly bind mannan. By attaching allergoids to mannan, the idea is to deliver the allergen directly to dendritic cells, accelerating uptake and steering the immune response toward tolerance rather than allergy. Preclinical work in human cell models and animal studies has shown that mannan-conjugated allergoids enhance allergen uptake, promote regulatory and protective immune responses, and have already demonstrated clinical efficacy in veterinary medicine.25PubMed Central. Novel vaccines targeting dendritic cells by coupling allergoids to mannan
This approach is still preclinical for humans, but the concept is compelling. If mannan conjugation proves out, it could reduce the number of doses required for effective immunotherapy and potentially boost response rates in patients who don’t respond well to current formulations.
The Economics of Immunotherapy
Immunotherapy takes years and requires either regular office visits or daily self-administration. It’s natural to wonder whether the investment is worth it compared to just managing symptoms with antihistamines and inhalers. The evidence strongly suggests it is. A systematic review evaluating 35 cost-effectiveness analyses found that 91% concluded allergen immunotherapy is cost-effective compared with standard symptom-management care alone, with both subcutaneous and sublingual routes demonstrating economic value. The economic case was strongest for patients with coexisting asthma and when models accounted for sustained benefits after treatment ends.26PubMed. Cost-Effectiveness of Allergen Immunotherapy for Allergic Rhinitis: A Systematic Review Reviewers have noted that most existing analyses only capture costs during the treatment period itself, meaning they underestimate the true value by ignoring the years of reduced medication use and the potential prevention of asthma that follow.27PubMed. Cost-effectiveness of allergen immunotherapy
The Biomarker Gap
One of the persistent frustrations in immunotherapy research is that there is no reliable way to predict before treatment starts whether a given patient will respond. You commit to three or more years of therapy, and you may not know for many months whether it’s working. Currently, no standardized biomarkers exist that reliably distinguish future responders from nonresponders, though several candidates have shown differences between the two groups in research settings.28PubMed Central. Mechanisms and biomarkers of successful allergen-specific immunotherapy Efforts to validate biomarkers are tied closely to understanding the immune mechanisms of therapy itself.29PubMed. Mechanisms of allergen immunotherapy supporting its disease-modifying effect
Component-resolved diagnostics, which identify exactly which molecular components of an allergen a patient reacts to, represent one pathway toward better patient selection. This approach can clarify whether someone reacting to grass pollen is sensitized to the major allergen that immunotherapy targets or to a cross-reactive minor component that treatment won’t address.30PubMed Central. Component resolved diagnosis: when should it be used? Better diagnostics at the front end could reduce the number of patients who spend years on therapy with little benefit, and help companies like Inmunotek match specific allergoid formulations to the patients most likely to respond.
Why Allergen Products Are Hard to Compare
One detail that patients and even some clinicians don’t fully appreciate is that allergen extracts from different manufacturers are not interchangeable the way generic drugs are. Every company’s product starts from natural biological material, and the resulting extract’s potency is measured against each manufacturer’s own in-house reference standard rather than a universal benchmark. That makes direct comparison between products from different companies essentially impossible using current regulatory tools. Each product has to be assessed individually for quality, safety, and efficacy.31PubMed Central. Quality requirements for allergen extracts and allergoids for allergen immunotherapy
This matters for patients because switching brands mid-treatment is not straightforward, and “allergy shots” from one clinic may contain a fundamentally different product than those from another. It also means that clinical results generated with Inmunotek’s specific allergoid preparations don’t automatically transfer to a competitor’s products, even if both are labeled for the same allergen. In a field moving toward precision medicine, this lack of standardization remains one of the biggest structural barriers to progress.